Select your country

Websites worldwide

Select a country to go to the website of the respective STADA sales company.

Australia (1)

Austria (1)

Belarus (1)

Belgium (1)

Bosnia-Herzegovina (1)

Bulgaria (1)

China (1)

Croatia (1)

Czech Republic (2)

Denmark (1)

France (1)

Germany (3)

Hungary (1)

Ireland (1)

Italy (1)

Montenegro (1)

Netherlands (2)

Poland (1)

Portugal (1)

Romania (1)

Saudi Arabia (1)

Serbia (1)

Slovakia (1)

Slovenia (1)

Spain (1)

Switzerland (1)

Thailand (1)

The Phillippines (1)

United Kingdom (3)

Vietnam (2)

< Back

News

  • 03/11/2025
  • Press Release

STADA has appointed Tomas Mihal as the new Head of Germany and member of the global STADA Executive Committee

  • Tomas Mihal has extensive expertise in the areas of consumer healthcare, generics, and specialty pharmaceuticals. He is expected to further expand the business in Germany and make a significant contribution to sustainable growth in all three STADA segments Consumer Healthcare (CHC), Generics (ALIUD), and Specialty (STADAPHARM).

  • The former head of STADA’s Czech operations returns to STADA after a successful international career stage as Vice-President and Regional Business Head for the Asia-Pacific region at Glenmark Pharmaceuticals.

  • CEO Peter Goldschmidt said: "Tomas Mihal will use his bold vision and entrepreneurial energy to ensure that our German business continues to drive forward its claim to market leadership in all our segments."

 

Bad Vilbel, Germany, November 3, 2025 – STADA has appointed Tomas Mihal (45) as the new Head of Germany. Since 1 November, he has been a member of the global management body, the STADA Executive Committee (SEC), reporting directly to CEO Peter Goldschmidt. Tomas Mihal is based at STADA headquarters in Bad Vilbel.

“I am very pleased that we can welcome Tomas Mihal, a passionate leader with international experience, back to STADA,” said Goldschmidt. Tomas previously headed the business in the Czech Republic from June 2019, playing a central role in the successful acquisition of the dietary supplement manufacturer Walmark. He used his leadership skills to create synergies and improve cooperation.

In his new role, Tomas will assume responsibility for the entire German business. The goal is to expand the market position in all three business segments – consumer healthcare (CHC), generics (ALIUD), and specialty pharmaceuticals (STADAPHARM) – and grow faster than the market in terms of sales and earnings.

“Tomas Mihal will use his bold vision and entrepreneurial energy to ensure that our German business continues to drive forward its claim to market leadership in all our segments. With his extensive experience and background, he will translate our strategic initiatives into measurable success for the German market, benefiting patients, partners, and the healthcare system,” said Goldschmidt.

Tomas Mihal added: “It is a great honor for me to take on responsibility for the STADA Group's most important market in terms of revenues and profit. Germany is a key growth driver with great potential. I look forward to translating this potential into sustainable, long-term growth and shaping the future of healthcare with my exceptional team.”

STADA is experiencing strong growth and is based on a three-pillar strategy of Consumer Healthcare, Generics, and Specialty. In the OTC market (non-prescription medicines), the STADA and ALIUD brands are in a close head-to-head race with Bayer for market leadership. ALIUD ranks second in prescription generics, while STADA is gaining market share in specialty pharmaceuticals with new biosimilars. “We want to further strengthen our position as a healthcare provider for Germany,” emphasizes Tomas Mihal.

With more than 20 years of industry experience in numerous management positions, Tomas Mihal brings comprehensive expertise in the areas of consumer healthcare, generics, and specialty pharmaceuticals. Born in Slovakia, he began his international career as a sales representative at Ipsen, followed by positions at Ratiopharm, Sandoz, Sanofi, and Zentiva. Most recently, Tomas worked at Glenmark Pharmaceuticals, where he was Vice-President and Regional Business Head for the Asia-Pacific (APAC) region, based in Singapore.

Tomas Mihal holds a degree in environmental engineering and a Ph.D. in biology. In his leisure time, he enjoys sports. Tomas Mihal is passionate about basketball and rock climbing.

Tomas Mihal, Executive Vice President Germany

Download

About STADA Arzneimittel AG
STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and specialty pharma. Worldwide, STADA Arzneimittel AG sells its products in over 100 countries. In financial year 2024, STADA achieved group sales of € 4,059 million and adjusted constant-currency earnings before interest, taxes, depreciation and amortization (adj. cc EBITDA) of € 886 million. As of 31 December 2024, STADA employed 11,649 people worldwide. 

Additional information for journalists
STADA Arzneimittel AG - Media Relations
Stadastrasse 2-18, 61118 Bad Vilbel - Germany
Phone: +49 (0) 6101 603-165
E-Mail: [email protected]

Additional information for capital market participants
STADA Arzneimittel AG - Investor & Creditor Relations
Stadastrasse 2-18, 61118 Bad Vilbel – Germany
Phone: +49 (0) 6101 603-4689
Fax: +49 (0) 6101 603-215
E-mail: [email protected]